NCT07316127RecruitingPhase 2
Immunoadsorption in Autoimmune Long COVID
A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake. This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months. This research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 8 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 12 Dec 2027
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07316127
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 1 Jan 2026 to the primary completion date, 12 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior interventional cardiac procedure within 3 months prior to randomization
- Poor performance score prior to the long COVID diagnosis (WHO performance \>0)
Other illness
- Medical history of clinically significant respiratory- or cardiovascular disease
- Active immunosuppresive treatment for systemic autoimmune disorders
- Diabetes type 1
- Solid organ malignancy in the last 5 years
- Active psychiatric disorder currently under treatment by a psychiatrist
Other
- BMI \> 35
- Pre-existing fatigue
- Pregnancy or breastfeeding
Who the study is looking for
- Long COVID based on the WHO-criteria
- PEM according to the DSQ-PEM
- BELL's functionality score 20-70%
- Good health prior to the long COVID diagnosis (WHO performance score 0)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AUMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.